Abagovomab clinical trials
How each study uses abagovomab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2002 (1)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Memorial Sloan Kettering Cancer Center (1) · AGO Study Group (1) · Menarini Group (1)
Studies
Open first, then newest update. How each study uses abagovomab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00058435Written as abagovomabHow we know
- Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer PatientsTerminatedPhase 2/3Menarini GroupNCT00418574Written as AbagovomabHow we know
- Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune ResponseCompletedPhase 1/2AGO Study GroupNCT00103545Written as ACA 125How we know
Codes
What other systems call abagovomab · ClinicalTrials.gg INT005059
- MeSH (NLM) C518318abagovomabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3YK0326U7XABAGOVOMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3603118abagovomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C26449AbagovomabOne source FDA
- DrugBank DB16077One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C518318 | abagovomab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3YK0326U7X | ABAGOVOMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3603118 | abagovomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C26449 | Abagovomab | One source FDA |
| DrugBank | DB16077 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.